Katie Falloon, MD

Ustekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.

Investigators from the Cleveland Clinic standardized diagnostic, follow-up, and treatment targets for 5 major EIMs: peripheral arthritis, axial arthritis, pyoderma gangrenosum, erythema nodosum, and uveitis.